

18/06/2026

Memo Therapeutics AG Presents Complete Phase II Clinical Trial Data for Potravitug in Kidney Transplant Recipients at the American Transplant Congress 2026

- *Complete SAFE KIDNEY II data confirm sustained reduction in viral load and resolution of biopsy-proven BKPyV-associated nephropathy with continued antiviral effect to 38 weeks*
- *Systematic literature review demonstrates the association between longer BKPyV infection duration and increased incidence of BKPyV-associated nephropathy*

Schlieren / Zurich, Switzerland, 18 June, 2026 – Memo Therapeutics AG (“MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, announces the presentation of data from its Phase II clinical trial of potravitug at the American Transplant Congress (ATC) 2026, taking place from 20-24 June in Boston, USA.

The oral presentation titled ‘Potravitug for the Treatment of BK Polyomavirus Infection in Kidney Transplant Recipients: A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Trial’, will be presented by Dr. Darshana Dadhania, Weill Cornell Medicine, New York Presbyterian Hospital (NYPH). This will feature complete data from the SAFE KIDNEY II study, including long-term follow-up, changes in immunosuppression, and serotyping data. These data support potravitug as a potential first-in-class targeted therapy to improve BK polyomavirus (BKPyV) clearance and kidney allograft outcome in kidney transplant recipients (KTRs).

Darshana Dadhania, M.D., M.S., Weill Cornell Medicine, NYPH, and a Principal Investigator, commented, “With no approved treatments available for kidney transplant recipients facing BKPyV infection, these comprehensive data on blood and tissue viral loads demonstrate potravitug’s potential as a targeted therapy for BKV, with sustained antiviral activity observed six months after the last active treatment.”

Potravitug demonstrated a sustained and significant antiviral effect where 24.4% of treated patients achieved undetectable BKPyV-DNAemia by week 38 versus 13.0% in the placebo group, with $>2\text{-log}_{10}$ viral load reductions occurring in 40.3% versus 24.7% of patients, respectively. By week 20, biopsy-proven BKPyV-associated nephropathy (BKPyVAN) had declined from 51.2% to 31.6% in the potravitug group, with no change observed in the placebo group. Potravitug was well tolerated, with no treatment-related serious adverse events reported.

A poster presentation of a systemic literature review, titled ‘BKPyV DNAemia Duration and Correlation with BKPyVAN’, was also accepted for ATC 2026. This systematic literature review conducted by Dr. David Wojciechowski, UTSW, Dallas TX, and Suphamai Bunnapradist, UCLA, Los Angeles CA revealed that longer persistence of BKPyV DNAemia was significantly associated with the incidence of BKPyVAN ($r=0.625$, $p=0.0019$).

Erik van den Berg, CEO of MTx, commented, “Following our data presented at the European Renal Association Congress earlier this month, these presentations of the complete SAFE KIDNEY II dataset at ATC 2026 continue to build a compelling clinical rationale for potravitug ahead of our planned SAFE KIDNEY 3 trial initiation later this year.”

Potravitug was granted orphan drug designation in the European Union in December 2025 and the Company plans to initiate a pivotal trial in 2026.

Oral presentation details:

Date: Tuesday, 23 June

Start Time: 8:30am EDT

Location: Thomas M. Menino Convention & Exhibition Center, Boston, MA

Room: Ballroom

Presentation Name: Potravitug for the Treatment of BK Polyomavirus Infection in Kidney Transplant Recipients: A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Presenter: Dr. Darshana Dadhania, Weill Cornell Medicine, New York Presbyterian Hospital

Poster presentation details:

Date: Tuesday, 23 June

Start Time: 2:30pm EDT

Location: Thomas M. Menino Convention & Exhibition Center, Boston, MA

Room: Exhibit Hall, Abstract D149

Presentation Name: BKPvV DNAemia Duration and Correlation with BKPvVAN

Presenter: Dr. David Wojciechowski, UT Southwestern Medical Center, Dallas TX

Contacts

Memo Therapeutics AG
info@memo-therapeutics.com

ICR Healthcare
Amber Fennell, Ashley Tapp
memotx@icrhealthcare.com
+44 (0)20 3709 5700



Head office

Memo Therapeutics AG
Wagistrasse 27
8952 Schlieren / Zurich
Switzerland

US office

Memo Therapeutics US, Inc.
6475 Rock Ridge School Road
Wilson, NC 27893
USA